Skip to main content

Table 1 Baseline demographics and characteristics, and clinical and comparative polysomnographic data from two subgroups of subjects.

From: Discontinuation of hypnotics during cognitive behavioural therapy for insomnia

  Hypnotics non-abusing
(N = 13)
Hypnotics-abusing
(N = 15)
Significance
Age [years] 45.23 (s.d. 14.53) 42.27 (s.d. 13.54) p = 0.58a
Gender [female : male] 9 : 4 10 : 5 p = 0.60b
Duration of disorder [insomnia length in months] 48 (IQR 17–204)* 60 (IQR 24–147)* p = 0.62c
Insomnia Severity Index [ISI] 16.54 (s.d. 4.19) 18.67 (s.d. 4.93) p = 0.23a
Epworth Sleepiness Scale [ESS] 12.15 (s.d. 5.83) 11.40 (s.d. 4.88) p = 0.71a
Beck Depression Inventory [BDI] 7.0 (IQR 2–11)* 6.5 (IQR 2.0–9.25)* p = 0.56c
Beck Anxiety Inventory [BAI] 10.31 (s.d. 6.21) 9.87 (s.d. 6.79) p = 0.86a
Hamilton Rating Scale for Depression [HAMD] 7.85 (s.d. 3.36) 5.80 (s.d. 3.38) p = 0.12a
modified Clinical Global Impression Severity [mCGI-S] 10 (IQR 9–11)* 8 (IQR 7–10)* p = 0.18c
Total sleep time TST [min] 344.69 (s.d. 58.14) 292.63 (s.d. 143.06) p = 0.23a
Sleep latency SL [min] 26.0 (IQR 7.15–47.45)* 27.2 (IQR 12.63–45.94)* p = 0.72c
Sleep efficiency SE [%] 75.5 (IQR 63.5–82.0)* 72.0 (IQR 64.0–81.0)* p = 0.86c
Wake after sleep onset WASO [min] 72.42 (s.d. 55.84) 87.37 (s.d. 58.72) p = 0.50a
Stage 1 [min] 36.50 (s.d. 19.74) 31.90 (s.d. 24.50) p = 0.59a
Stage 2 [min] 153.96 (s.d. 82.50) 154.37 (s.d. 40.50) p = 0.98a
Stage 3+4 [min] 105.40 (s.d. 51.00) 120.74 (s.d. 44.50) p = 0.04 a
REM [min] 55.90 (s.d. 45.00) 76.77 (s.d. 39.00) p = 0.04 a
  1. * Data are presented as median (interquartile range) due to non-normal data distribution. Characters in bold indicate significance (p < 0.05).
  2. a – One-way ANOVA; b – Fischer Exact Test; c – Mann-Whitney U Test;
  3. IQR – interquartile range; s.d. – standard deviation; N.S. – non significant